dostarlimab
Sign in to saveDostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- PD-1
- Drug.tradename
- Jemperli
- Drug.MedlinePlus
- a621030
- Drug.DailyMedID
- Dostarlimab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FF07
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 2022215-59-2
via Wikipedia infobox
Article
18 sectionsContents
- Medical uses
- Endometrial cancer
- Solid tumors
- Colorectal cancer
- Side effects
- Immune-mediated adverse reactions
- Pregnancy and lactation
- Hepatotoxicity
- Pharmacology
- Mechanism of action
- Efficacy
- History
- Society and culture
- Legal status
- Economics
- References
- Further reading
- External links
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional side effects reported in the European Union include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).